Agilent Expands SureGuide Portfolio with CRISPR-based Products to Accelerate Disease Research
October 17 2017 - 8:30AM
Business Wire
New CRISPR-based Transcriptional Activation and Interference
(a/i) Libraries
Agilent Technologies Inc. (NYSE: A) today announced the first
expansion of the SureGuide pooled CRISPR libraries for functional
genomics, offering pooled libraries for CRISPR activation and
interference (CRISPR a/i). The announcement was made at the at the
American Society for Human Genetics Conference (ASHG), being held
October 17 - 21 in Orlando, Florida.
Every SureGuide CRISPR library is synthesized using Agilent’s
advanced SurePrint DNA synthesis platform, simultaneously printing
billions of DNA bases with industry-leading sequence fidelity and
superior representation. The flexibility of Agilent's platform now
brings to researchers CRISPR a/i libraries incorporating gene
targets developed by the University of California, San Francisco,
CA.
“CRISPR activation and repression are novel research
applications that will dramatically expand the utility of genome
engineering, potentially revolutionizing disease research,” said
Kamni Vijay, vice president and general manager of Agilent's
Genomics Solutions Division and Clinical Applications Division.
“This expansion of our SureGuide portfolio is an example of
Agilent’s continued commitment to enabling new discoveries using
CRISPR technology.”
Genetic screens using pooled libraries are typically performed
to locate and identify genes that are involved in cellular
response, such as in signaling pathways, or to discover the
function of novel genes. While CRISPR knock-outs target individual
genetic regions, CRISPR a/i libraries target transcription start
sites throughout the genome. These novel tools allow researchers to
turn up, or down, the expression of individual genes and screen the
resulting phenotypes. These new libraries complement the existing
offering of genome-wide libraries and promise to accelerate drug
discovery and functional genomics research.
SureGuide CRISPR a/i libraries are offered in both
Ready-to-Clone and Ready-to-Amplify formats. With Ready-to-Clone
libraries, scientists can specify the sequence of each guide in the
library or choose from validated predefined subsets, such as
kinases or cancer genes, of the genome. With Ready-to-Amplify
libraries, scientists can fully design every aspect of the library
including the tracer sequence, allowing for the use of alternative
delivery systems, guide structures, and cloning approaches while
targeting any organism of choice.
Agilent will host a workshop on October 20th at ASHG, where the
CRISPR a/i libraries and workflow will be highlighted. In addition,
customers will speak about their novel research applications using
SureGuide CRISPR Libraries.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global
leader in life sciences, diagnostics, and applied chemical markets.
With more than 50 years of insight and innovation, Agilent
instruments, software, services, solutions, and people provide
trusted answers to its customers’ most challenging questions. The
company generated revenues of $4.20 billion in fiscal 2016 and
employs about 13,000 people worldwide. Information about Agilent is
available at www.agilent.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171017005699/en/
Agilent TechnologiesNaomi Goumillout, +1
781-314-1862naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024